Debate exists on the disease biology and course of primary large cell neuroendocrine carcinoma (LCNEC) of larynx, being classified as a variant of atypical carcinoid by the World Health Organisation-2005 classification, while literature of its aggressive behavior indicating poorly differentiated neuroendocrine carcinoma (akin to pulmonary LCNEC) exists. The utility of dual tracer positron emission tomography/ computed tomography ( 68 Ga-DOTATATE and 18 F-fluorodeoxyglucose) in deciphering the dynamic tumor biology and feasibility of peptide receptor radionuclide therapy (PRRT) is illustrated in metastatic LCNEC of epiglottis after disease progression following conventional chemoradiotherapy. Relatively, atypical sites of soft-tissue metastases (subcutaneous tissue of arm, scrotal sac, peritoneum, and lamina of thyroid cartilage) and xiphisternum and disease stabilization following 177 Lu-DOTATATE PRRT were other noteworthy unique aspects of this report.
INTRODUCTION
The disease management and prognosis of the neuroendocrine tumors (NETs) is dependent on the histological subtype (determining tumor biology), site, and stage of the disease. Laryngeal NETs are the most common primary site among head and neck NETs, though comprising <1% of all laryngeal neoplasms. [1] We herein describe a 60-year-old man of primary large cell neuroendocrine carcinoma (LCNEC) of epiglottis with atypical sites of metastases, who initially demonstrated progressive disease on conventional chemoradiotherapy, but subsequently showed disease stabilization following peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. 
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DISCUSSION
According to the 2005 World Health Organization (WHO)
classification of head and neck tumors, NET of the larynx is divided into five histologic subtypes -typical carcinoid (TC), atypical carcinoid (AC), small cell NEC (SCNEC), combined small cell with non-small cell carcinoma, and paraganglioma. [2] In the same classification system, primary laryngeal LCNEC had been considered as a variant of AC in contrast to the well-known pulmonary LCNEC which is categorized as poorly differentiated NECs. [2] On the other hand, reports exist on its poor outcome emphasizing reclassification of LCNEC as variants of small cell carcinoma (poorly differentiated NEC). [3, 4] In one report, patients of AC more often presented with Stage I and II disease while those with LCNEC presented with Stage III and IV disease.
[4] In the same meta-analysis, the 5-year disease-specific survival was found to be 100% for TC, 53% for AC, 19% for SCNEC, and 15% for LCNEC.
[4] Other authors have reported a favorable outcome of LCNEC indicating the possibility of a variant in LCNEC with comparatively slower disease course. [5] Hence, there is a need for further exploring and studying its biology. [5] 68 Ga-DOTATATE (Krenning score-3) made 177 Lu-DOTATATE-based PRRT a feasible treatment option, which resulted in disease stabilization of most of the lesions (complete response of peritoneal deposit) and no disease progression at the timing of writing this report at 9 months.
CONCLUSION
The described case underscores the potential role of dual tracer PET-CT molecular imaging in assessing the disease biology of metastatic lesions in LCNEC including indicating the feasibility of PRRT. SSTR-targeted 68 Ga-DOTATATE PET-CT is a useful investigation in assessment, deciding on the feasibility of PRRT and follow-up akin to other NETs, while FDG uptake helps in prognosticating the disease. PRRT, in addition to concurrent chemo-radiotherapy, offers another potential therapeutic approach in receptor-positive cases of metastatic LCNEC and may result in longer survival.
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